AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 191 min read$TELA

Getz Heather C purchased $8K of TELA

Getz Heather C (Chief Executive Officer) purchased 12,500 shares of TELA Bio, Inc. (TELA) at $0.66 on 2026-08-17.

Original reporting
SEC EDGAR · Getz Heather C
Published Aug 19, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TELA
Neutral
medium confidence
Mentioned
$TELA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TELANeutralLow
01

Why it matters

The disclosed purchase is modest and unlikely to move the stock, but it adds to the insider activity record.

02

Market read

A small insider buy with limited immediate market impact; useful for tracking insider sentiment over time.

03

What to watch

Potential upcoming clinical data or financing events not disclosed in this filing.

Relevance 4/10Novelty 6/10Timing: post‑market filing on Aug 19, 2026

Background

Form 4 filings disclose insider trades; investors watch CEO purchases for confidence cues.

Company-level read

Ticker impact

$TELANeutralMedium confidence
Context

CEO Heather Getz purchased 12,500 shares of TELA for $8,311, a direct insider buy disclosed in a Form 4 filing.

Expected impact

Minimal short‑term move; potential slight upside if market interprets as confidence.

Evidence & confidence

The transaction is under $10k and represents a tiny fraction of total shares outstanding, so any price effect is likely muted.

Market effects

Sector

None; biotech sector not materially affected by a small insider buy.

Regional

None; company is US‑listed with limited regional relevance.

Global

Low; isolated insider transaction.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong confidence signal.

Key entities

  • Executive
    Heather Getz

    Chief Executive Officer of TELA Bio, Inc.

  • Company
    TELA Bio, Inc.

    Biotech firm focused on oncology therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TELA insider trading history →

Related articles

AUG 19
$TELAMed

TELA Bio (TELA) Q2 2026 Earnings Call Transcript

TELA Bio reported Q2 2026 revenue of $19.3M, down 4% YoY, driven by declines in OviTex PRS unit volumes and price-mix headwinds. International revenue grew 26% YoY, while gross margin improved to 72%. Net loss was $11.3M, and cash reserves decreased to $30.4M. Management cited competitive pressures and slower sales rep productivity as challenges, while highlighting market share gains in hernia products and plans to reduce costs.

fool.com3 min
AUG 10
$TELAMed

TELA Bio, Inc. (TELA): Results of Operations and Financial Condition

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results fo

SEC EDGAR 8-K4 min